Skip to main content
    D

    Day One Biopharmaceuticals Inc (DAWN)

    Official site

    BIOTECHNOLOGY

    $21.53
    +0.00 (+0.00%)

    Last updated: Apr 23, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(8/19)
    Avg Surprise
    +18.18%

    Upcoming Estimates

    Results pendingPeriod ending Jun 30, 2026
    EPS Consensus-$0.16
    Range-$0.28 - -$0.03
    6 analysts
    EPS Revisions
    1
    3
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.14-8.9%
    60d ago-$0.14-8.9%
    30d ago-$0.14-11.5%
    7d ago-$0.13-18.3%
    Current-$0.16
    Revenue Consensus
    $57.13M
    Range$53.00M - $63.10M
    9 analysts
    Last 12 of 22 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Jun 26EST
    Date TBD
    --$0.16-$0.28 - -$0.03--6
    1
    3
    30d
    -
    Dec 25
    Reported Feb 24
    -$0.21-$0.19N/A-8.81%Miss--+66.7%
    Sep 25
    Reported Nov 4
    -$0.19-$0.29-$0.32 - -$0.21+34.48%Beat7
    0
    1
    30d
    -150.0%
    Jun 25
    Reported Aug 5
    -$0.29-$0.35-$0.40 - -$0.25+17.38%Beat6
    0
    1
    30d
    -480.0%
    Mar 25
    Reported May 6
    -$0.35-$0.42-$0.73 - -$0.33+16.67%Beat7
    0
    2
    30d
    +51.4%
    Dec 24
    Reported Feb 25
    -$0.63-$0.46N/A-36.22%Miss--+1.6%
    Sep 24
    Reported Oct 30
    $0.38-$0.32-$0.73 - $0.30+220.41%Beat8
    2
    0
    30d
    +170.4%
    Jun 24
    Reported Jul 30
    -$0.05-$0.75-$1.27 - -$0.24+93.33%Beat8
    1
    1
    30d
    +91.8%
    Mar 24
    Reported May 6
    -$0.72-$0.66-$0.71 - -$0.63-9.09%Miss8
    No revisions (30d)
    -22.0%
    Dec 23
    Reported Feb 26
    -$0.64-$0.58N/A-10.34%Miss---14.3%
    Sep 23
    Reported Nov 6
    -$0.54-$0.60-$0.70 - -$0.50+10.00%Beat9
    No revisions (30d)
    -1.9%
    Jun 23
    Reported Aug 7
    -$0.61-$0.61-$0.66 - -$0.550.00%In line9
    No revisions (30d)
    -1.7%
    Mar 23
    Reported May 1
    -$0.59-$0.59-$0.62 - -$0.550.00%In line9
    No revisions (30d)
    -22.9%

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 18.2% above its 50-day moving average, and the 50-day average is above the 200-day average. The 14-day RSI is 80.3, above 70, the overbought line.

    Moving Averages

    SMA 10$21.48
    SMA 20$21.46
    SMA 50$18.21
    SMA 200$10.72
    EMA 10$21.48
    EMA 20$21.13
    EMA 50$18.70
    EMA 200$12.40

    MACD

    Line: 0.74Signal: 1.00Hist: -0.26

    ADX

    ADX: 65.7+DI: 53.0-DI: 9.7

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down4.0
    PSAR$21.43

    Bollinger Bands

    Upper Band$21.53
    Lower Band$21.39
    %B Position65%(Middle)
    Band Width1.00

    RSI (14-Day)

    Overbought
    80.3

    Momentum Oscillators

    Stoch %K96.3
    Stoch %D91.3
    Williams %RN/A
    ROC (10d)0.2%
    Momentum0.05
    CCI (20d)191.3
    MFI (14d)65.2

    Volatility Measures

    ATR (14d)$0.16(0.7%)
    StdDev (20d)0.03
    Hist Vol1.5%(Low)

    Volume Flow

    VWAP$21.53
    OBV135.5M
    AD Line56.2M
    CMF (20d)0.078

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol RatioN/A
    VWMA (20d)$21.46

    Pivot Points

    R3$21.58
    R2$21.56
    R1$21.54
    Pivot Point$21.52
    S1$21.50
    S2$21.48
    S3$21.46

    Advanced Oscillators

    TSI61.68
    Ultimate Osc58.6
    KST264.95

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about DAWN

    News

    No news available

    Company news will appear here when available

    Day One Biopharmaceuticals Competitors

    Peers by sector and size for Day One Biopharmaceuticals (DAWN) include Palvella Therapeutics, Schrodinger and Perrigo Company.

    Sector: Healthcare

    DAWN Earnings: Beat Rate

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    41.0%

    DAWN Earnings Call

    The latest DAWN earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    DAWN ETF Holders

    See insider activity

    Updated Feb 26, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.